The Legal 500

United States

United States > Litigation > Mass tort and class action: plaintiff representation – pharmaceuticals and medical devices

Editorial sections

Index of tables

  1. Mass tort and class action: plaintiff representation – pharmaceuticals and medical devices
  2. Leading lawyers

Leading lawyers

    • Andy Birchfield Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.
    • Michael Burg Burg Simpson Eldredge Hersh & Jardine, P.C.
    • Russ Herman Herman, Herman & Katz LLC
    • W. Mark Lanier The Lanier Law Firm
    • Mike Papantonio Levin Papantonio Thomas Mitchell Rafferty & Proctor, P.A.
    • Michelle Parfitt Ashcraft & Gerel LLP
    • Christopher Seeger Seeger Weiss LLP

The ‘excellentBurg Simpson Eldredge Hersh & Jardine, P.C. is ‘one of the leaders in this field’ and is praised for ‘seeing a case through to trial if necessary’. The firm remains involved in the Yaz /Yasmin multi-district litigation (MDL), where practice head Michael Burg is co-lead counsel, Seth Katz serves as the chair of the discovery committee and Janet Abaray is co-chair of the science and expert committee. In 2013 the firm was also involved in negotiating a global settlement with Bayer with regard to gall bladder injuries; it recently entered into negotiations with the company regarding compensation for venous injuries suffered by over 8000 women. Katz, who is particularly ‘strong on electronic discovery’, is currently serving as co-lead counsel in the Pradaxa litigation, and is also a member of the plaintiffs’ steering committee in the MDL involving DePuy Orthopaedics’ recalled ASR XL metal-on-metal hip device and the alleged failure of its ASR XL Acetabular Hip System. Abaray is the lead attorney in the Depakote products liability claims, where depositions are ongoing and expert witnesses have been retained. Michael Burg and Peter Burg ‘are experienced and highly capable trial lawyers who are absolutely devoted to their clients and practices’.

Herman, Herman & Katz LLC has an active practice operating out of New Orleans. The firm is currently representing plaintiffs in Granuflo litigation against Fresenius Medical Care; the case was established as an MDL in 2013, with James Klick serving on the plaintiffs’ executive committee and of counsel Joseph Kott serving as co-chair of the science committee. The firm is also active in the TYLENOL MDL, with Leonard Davis serving on the plaintiffs’ steering committee, and its role in the Vioxx litigation recently saw it negotiating a $23m settlement for the reimbursement of prescription costs; Russ Herman serves as the plaintiffs’ liaison counsel and chair of the executive committee, Davis is an ex-officio member of the plaintiffs’ steering committee and Stephen Herman is co-chair of the sales and marketing committee, insurance committee and a member of the drafting team.

The ‘highly regardedLevin Papantonio Thomas Mitchell Rafferty & Proctor, P.A. is headquartered in northwest Florida, and its track record includes handling litigation involving Actos, Accutane, GranuFlo, antidepressants and DePuy hip implants; in the latter, Ben Gordon serves on the plaintiffs’ executive committee and has been appointed as co-chair of the science and expert committee. Other key names in the team Troy Rafferty and Timothy O’Brien are involved in the gadolinium-based contrast agent litigation and Fosamax product liability litigation respectively. Mike Papantonio is a ‘good trial lawyer’.

Lieff Cabraser Heimann & Bernstein, LLP is ‘very good’, particularly in hip replacement cases; it remains active in the DePuy artificial hip litigation, where Wendy Fleishman serves on the plaintiffs’ steering committee in the MDL and Robert Nelson serves on the plaintiffs’ steering committee in co-ordinated proceedings in the California state court. Other activities in 2013 included filing claims in the Medtronic InFUSE litigation, where injuries are alleged to have arisen from the off-label use of the InFUSE bone graft. The firm is also active in pharmaceutical litigation such as the Actos litigation; Donald Arbitblit serves on the science committee. Practice head Elizabeth Cabraser is a ‘stand-out name’ in this area. Cabraser, Arbitblit and Nelson are based in the firm’s San Francisco office, while Fleishman is New York-based.

Name partner W Mark Lanier at The Lanier Law Firm is a ‘major player’; opponents note that when this ‘formidable’ attorney is on the other side that they ‘stand up and take notice’. The firm, which has offices in Texas, California and New York, has represented clients in litigation involving DePuy hip replacements, transvaginal mesh, failed knee replacements, CHANTIX and Paxil. The firm is currently representing plaintiffs in claims against Intuitive Surgical, which manufactures the da Vinci Surgical Robot, for failure to properly train surgeons on the proper use of the product; plaintiffs claim to have suffered injuries following surgery involving the Robot, including tears or burns to blood vessels, intestines and other internal organs. New York-based pharmaceutical litigation chair Richard Meadow continues to serve on a number of plaintiffs’ steering committees.

The ‘very professional’ team at Levin, Fishbein, Sedran & Berman is praised by peers for ‘getting the ball moving’ in litigation and is ‘fabulous in pulmonary hypertension cases’. The firm is currently lead plaintiffs’ counsel in the nationwide class action concerning diet drugs, representing clients in both the trial and appellate courts. The ‘excellent’ Arnold Levin serves on the negotiating plaintiffs’ counsel committee in the Vioxx litigation. Frederick Longer and Michael Fishbein are also recommended. The team is based in the firm’s sole office in Philadelphia.

Seeger Weiss LLP’s ‘very active’ team is made up of ‘civil, ethical lawyers who do their job well’; it operates from offices in New York, New Jersey and Pennsylvania. Co-founder Christopher Seeger is a ‘very good organizer’ and continues to act in MDLs; for example he is on the plaintiffs’ steering committee in the Actos litigation, and has been appointed to the plaintiffs’ executive committee in the the DePuy artificial hip litigation. David Buchanan, who is ‘excellent’, is noted for his expertise in electronic discovery.

Ashcraft & Gerel LLP’s 20 fee-earner team operates from offices in Washington DC, Virginia and Maryland. It represents plaintiffs in litigation involving Actos, the da Vinci Surgical System, GranuFlo, Pradaxa and TYLENOL. Michelle Parfitt and James Green in the firm’s Washington DC office are ‘top names’ in this area; the latter has been appointed to serve on the MDL committees for prescription drugs including Fosamax, Rezulin and Zyprexa.

Beasley, Allen, Crow, Methvin, Portis & Miles, P.C., which is based in Montgomery, Alabama, is praised by peers for its ‘good work’. Highlights included Frank Woodson’s appointment to serve on the plaintiffs’ steering committee for the GranuFlo litigation and Roger Smith’s appointment to serve on the plaintiffs’ steering committee for the Mirena IUD litigation. Andy Birchfield heads the mass torts practice, which includes P Leigh O’Dell, and which has recently added seven of counsel.

Press releases

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

Press Releases worldwide

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to
  • Exempted Limited Partnership Law, 2014

    The Exempted Limited Partnership Law, 2014 (the New ELP Law ) has replaced the Exempted Limited Partnership Law (2013 Revision) (the Previous Law ). The New Law includes significant changes to the Cayman Islands' statutory framework regulating exempted limited partnerships ( ELPs ) that will increase the attractiveness of ELPs and will be appreciated by managers, investors and creditors alike. Private equity sponsors in particular will notice substantial improvements that are indicative of Cayman's continuing commitment to balanced and commercially sensible legislation. Read more...
  • Restructuring and insolvency in Luxembourg (part 2)

    RESTRUCTURING - COURT PROCEDURES
  • Enhancements to the Companies (Jersey) Law 1991

    On 23 May 2014, the States of Jersey passed the Companies (Amendment No. 11) (Jersey) Law 201- (the Amendment Law ).  This will now be sent to the UK Privy Council for consideration, then laid before the States of Jersey for a final time before coming into force.  The latest information we have is that the Privy Council will be approving the law on 19 July 2014 and it may come into effect as soon as 4 August 2014.
  • Joost Fanoy appointed partner at BarentsKrans

    The Hague, 4 July 2014 - BarentsKrans has appointed Joost Fanoy as a partner in the Antitrust & Public Procurement department, effective as of July 1, 2014. Joost specializes in European law in general with a particular focus on European and Dutch competition, public procurement and state aid law and is the head of the Antitrust and Public Procurement Practice Group. Joost is also a member of the Cartel damages team of BarentsKrans.
  • PineBridge Acquires 50% Stake in Romatem

    PineBridge Investments Middle East, a global multi-asset class investment manager with regional headquarters in Bahrain, and nearly 60 years of experience in emerging and developed markets, has acquired a 50% equity stake in Romatem, the leading physical therapy and rehabilitation services chain in Turkey.
    - Paksoy
  • Isbank Issued USD 750 Million Notes

    Isbank issued 750 million USD notes under its GMTN programme established in 2013. The notes are listed on the Irish Stock Exchange and bear interest at the rate of 5 % with a maturity date 2021. Mr. Omer Collak (partner) and Mr. Baris Kencebay (head of tax practice) have acted for the joint lead managers Barclays, Citigroup, HSBC, National Bank of Abu Dhabi and The Royal Bank of Scotland.
    - Paksoy
  • Halkbank Issued USD 500 Million Notes

    Halkbank issued five-year term fixed interest rate US currency notes, with a total amount of USD 500 million  with an interest rate of 4.765 %  and an annual coupon rate of 4.750 %. The notes offered the lowest borrowing rate in the first five-month period of 2014, and total demand rose nearly nine-fold due to high investor interest. The note issuance drew great interest from international investors settled in the Middle East and Asia, as well as those investors based in the US and Europe. Mr Omer Collak (partner) and Mr Baris Kencebay (head of tax practice) have advised the joint lead managers.
    - Paksoy
  • Turkiye Finans to Issue Ringgit Sukuk to Raise Up to MYR 3 Billion In Malaysia

    Turkiye Finans issued the first ringgit sukuk originating from Turkey. The bank initially raised MYR 1 billion with a five-year commodity sukuk on June 30, with an annual return of 6 %. The sukuk under the programme will have tenure of one to 20 years. Funds raised will go towards general corporate purposes. The sukuk will be issued through TF Varlik Kiralama A.S., a wholly-owned subsidiary of Turkiye Finans. Malaysia's RAM Ratings has accorded the programme an indicative long-term rating of AA3. HSBC Amanah Malaysia and Standard Chartered Saadiq were the joint advisers. Mr Omer Collak (partner) and Mr Baris Kencebay (head of tax practice) have advised Turkiye Finans and the issuer TF Varlik Kiralama A.S.
    - Paksoy
  • Ziraat Bank Established GMTN Programme to Issue Bonds Worth USD 2 Billion

    Ziraat Bank, the largest state owned bank of Turkey, established GMTN programme on 21 May 2014, for the notes to be issued up to  USD 2 billion listed on Irish Stock Exchange. The notes are unconditional, unsubordinated and unsecured obligations, and rank  pari-passu with Ziraat Bank's other senior unsecured obligations.
    - Paksoy
  • Vakifbank Sells EUR 500 Million Notes Under USD 5 Billion GMTN Programme

    Vakifbank issued EUR 500 million 5-year unsecured and unsubordinated notes under the first GMTN programme of Turkey established in 2013. The notes are listed on Irish Stock Exchange and bear interest at the rate of 3.5 % p.a. with a maturity date 17 June 2019. This is the very first EUR denominated RegS offering of a Turkish entity.
    - Paksoy